Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters

Database
Country/Region as subject
Language
Affiliation country
Publication year range
1.
JAMA ; 324(6): 571-580, 2020 08 11.
Article in English | MEDLINE | ID: mdl-32780139

ABSTRACT

Importance: Slowing myopia progression could decrease the risk of sight-threatening complications. Objective: To determine whether soft multifocal contact lenses slow myopia progression in children, and whether high add power (+2.50 D) slows myopia progression more than medium (+1.50 D) add power lenses. Design, Setting, and Participants: A double-masked randomized clinical trial that took place at 2 optometry schools located in Columbus, Ohio, and Houston, Texas. A total of 294 consecutive eligible children aged 7 to 11 years with -0.75 D to -5.00 D of spherical component myopia and less than 1.00 D astigmatism were enrolled between September 22, 2014, and June 20, 2016. Follow-up was completed June 24, 2019. Interventions: Participants were randomly assigned to wear high add power (n = 98), medium add power (n = 98), or single-vision (n = 98) contact lenses. Main Outcomes and Measures: The primary outcome was the 3-year change in cycloplegic spherical equivalent autorefraction, as measured by the mean of 10 autorefraction readings. There were 11 secondary end points, 4 of which were analyzed for this study, including 3-year eye growth. Results: Among 294 randomized participants, 292 (99%) were included in the analyses (mean [SD] age, 10.3 [1.2] years; 177 [60.2%] were female; mean [SD] spherical equivalent refractive error, -2.39 [1.00] D). Adjusted 3-year myopia progression was -0.60 D for high add power, -0.89 D for medium add power, and -1.05 D for single-vision contact lenses. The difference in progression was 0.46 D (95% CI, 0.29-0.63) for high add power vs single vision, 0.30 D (95% CI, 0.13-0.47) for high add vs medium add power, and 0.16 D (95% CI, -0.01 to 0.33) for medium add power vs single vision. Of the 4 secondary end points, there were no statistically significant differences between the groups for 3 of the end points. Adjusted mean eye growth was 0.42 mm for high add power, 0.58 mm for medium add power, and 0.66 mm for single vision. The difference in eye growth was -0.23 mm (95% CI, -0.30 to -0.17) for high add power vs single vision, -0.16 mm (95% CI, -0.23 to -0.09) for high add vs medium add power, and -0.07 mm (95% CI, -0.14 to -0.01) for medium add power vs single vision. Conclusions and Relevance: Among children with myopia, treatment with high add power multifocal contact lenses significantly reduced the rate of myopia progression over 3 years compared with medium add power multifocal and single-vision contact lenses. However, further research is needed to understand the clinical importance of the observed differences. Trial Registration: ClinicalTrials.gov Identifier: NCT02255474.


Subject(s)
Contact Lenses, Hydrophilic , Myopia/rehabilitation , Child , Contact Lenses, Hydrophilic/adverse effects , Disease Progression , Double-Blind Method , Female , Humans , Linear Models , Male , Ohio , Refraction, Ocular , Sample Size , Texas , Time Factors , Treatment Outcome
2.
Cont Lens Anterior Eye ; 31(4): 201-6, 2008 Aug.
Article in English | MEDLINE | ID: mdl-18595770

ABSTRACT

A presumed case of fungal keratitis is presented. Confocal images highlight the advantage of using such technology to follow therapeutic progress, particularly when standard laboratory testing is inconclusive. This case also demonstrates the importance of continued patient education regarding overall compliance and lens care.


Subject(s)
Corneal Ulcer/diagnosis , Eye Infections, Fungal/diagnosis , Mycoses/diagnosis , Adult , Anti-Infective Agents/therapeutic use , Antifungal Agents/therapeutic use , Aza Compounds/therapeutic use , Corneal Ulcer/drug therapy , Corneal Ulcer/microbiology , Drug Therapy, Combination , Eye Infections, Fungal/drug therapy , Eye Infections, Fungal/microbiology , Fluoroquinolones , Fusarium , Humans , Male , Microscopy, Confocal , Moxifloxacin , Mycoses/drug therapy , Mycoses/microbiology , Natamycin/therapeutic use , Quinolines/therapeutic use , Tobramycin/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL